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Background: The ability to distinguish malignant from benign Retroperitoneal Fibrosis (RPF) 25 
and to select the patients who are likely to respond to steroid treatment using a non-26 
invasive test would be a major step forward in the management of patients with RPF. 27 
Objective: To prospectively evaluate the potential of 18F-FDG-PET to improve clinical 28 
decision-making and management of RPF patients. 29 
Design, setting and participants: 122 RPF patients have been assessed and managed by a 30 
multi-disciplinary RPF service between January 2012 and December 2015. 78 of these 31 
patients have undergone 101 FDG-PET scans, as well as CT and blood tests. Management 32 
was based on the findings of these investigations. Median follow up was 16 months. 33 
Results and limitations:  34 
0/24(0%) patients with a negative 18F-FDG-PET had malignancy on biopsy (NPV 100%).  35 
18F-FDG-PET identified malignancy in 4/4 (100%) patients prior to biopsy. All 4 patients had 36 
a highly avid PET (maximum standardised uptake value ≥ 4) with atypical distribution of 37 
avidity. 38 
18F-FDG-PET detected avidity in 19/38 (50%) patients with normal inflammatory markers 39 
and demonstrated no avidity in 10/63 (16%) patients with raised markers.  40 
Patients with a highly avid PET were significantly more likely to respond to steroids 41 
compared to those with low avidity or negative PET (9/11(82%) vs 3/24(12%), p<0.01; and 42 
9/11(82%) vs 0/14(0%); p<0.01).   43 
Limitations include the small number of patients and the predominantly tertiary referrals 44 
which may represent patients with particularly problematic RPF. 45 
Conclusions: This study has established a promising role for 18F-FDG-PET in optimising and 46 
individualising the treatment of RPF patients.  47 
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Patient summary: This study shows that a FDG-PET scan could reduce the need for biopsy 48 
because it is able to distinguish cancer from non-cancerous RPF, and may be better than 49 
blood tests at assessing and monitoring RPF. It also appears to predict response to steroids 50 





















Retroperitoneal fibrosis (RPF) can be a challenging disease to manage and there are no 70 
published guidelines. Important considerations include the identification of malignancy 71 
which can mimic RPF; the management of ureteric obstruction; the role of biopsy and 72 
associated complications; minimising side effects from long courses of steroids and reducing 73 
morbidity from major abdominal surgery, viz, ureterolysis [1,2]. Other challenges include 74 
delayed diagnosis; intractable pain; morbidity from ureteric stents and the operations to 75 
change them. 76 
 77 
Helpful in addressing some of these challenges would be a non-invasive, safe and reliable 78 
method of firstly, excluding malignancy without the need for biopsy and secondly, predicting 79 
and monitoring response to immuno-suppressants. A number of approaches have been 80 
investigated but all have limitations.  81 
 82 
CT or MRI are valuable but may not definitively exclude malignancy and the degree of 83 
contrast enhancement does not appear to reflect metabolic activity within the RPF or 84 
predict response to steroids [3]. This inability to distinguish malignant from benign RPF on 85 
imaging necessitates biopsy in many cases. However, RPF does not always produce a 86 
discrete mass amenable to biopsy and even if a mass is present, its proximity to major blood 87 
vessels may make percutaneous biopsy not feasible. These problems can lead to biopsy 88 
being non-diagnostic in up to 33% of cases [4]. Open surgical biopsy has better yields but is 89 
more invasive [5]. Furthermore, the clinical implications of a ‘positive’ biopsy are not clear 90 
since the histological characteristics of RPF are not well-defined and the biopsy protocol is 91 
not standardised in terms of number of biopsies or immune-histochemical panel needed 92 
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[2,6]. In practice these limitations mean that many patients commence drug treatment 93 
without prior histological exclusion of malignancy. 94 
 95 
RPF, like many other fibro-inflammatory disorders, appears to have both an active 96 
inflammatory phase and a more chronic, non-inflammatory fibrotic phase [7]. Distinguishing 97 
between these phases could be crucial in guiding clinical management and allowing 98 
individualized treatment; for example, if inflammatory RPF responded to steroids better 99 
than predominantly fibrotic RPF. 100 
Currently the best surrogates for identifying inflammatory activity within RPF are elevated 101 
serum inflammatory markers – Erythrocyte Sedimentation Rate (ESR) and C-Reactive Protein 102 
(CRP) - and in most practices form the basis of both decisions to treat with steroids and 103 
assessing response. However, these markers are non-specific [8] and their use may be 104 
problematic in patients who have other reasons for raised inflammatory markers (e.g. UTI, 105 
stents, systemic autoimmune disease). Furthermore, intense inflammatory activity in small 106 
but potentially clinically significant plaques may not generate changes in systemic 107 
inflammatory markers.   108 
 109 
These dilemmas have led to investigations of alternative imaging modalities in RPF. Case 110 
reports and preliminary studies have suggested a possible role for FDG-PET (table 1). Interest 111 
in FDG-PET for the evaluation of inflammation began with the observation that FDG shows 112 
increased uptake not only in malignant cells, but also in inflammatory cells [9]. Subsequent 113 
work has addressed its potential value in inflammatory disorders such as vasculitis, 114 
sarcoidosis and automimmune conditions [10,11]. FDG-PET is also able to identify actively 115 
inflamed joints with higher sensitivity than clinical symptoms or ESR/CRP [12].  116 
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Based on these initial reports we hypothesised that 18F-FDG-PET, because of both the 117 
anatomical and functional information that it can provide, might identify the rare instances 118 
of malignancy mimicking RPF; might differentiate between inflammatory and fibrotic RPF 119 
thereby shaping treatment decisions; and might provide an accurate method of monitoring 120 




















A multi-disciplinary RPF service was established at Guy’s Hospital in London in January 2012. 139 
The protocol for investigation of patients evolved over the first year, with 18F-FDG-PET 140 
initially being used only to resolve uncertainties with regard to malignancy. From July 2013 141 
patients requiring imaging were investigated using a combination of standard CT and 18F-142 
FDG-PET. Patients who were asymptomatic and appeared to have no clinical issues related 143 
to RPF did not have FDG-PET. Data on all patients undergoing 18F-FDG-PET between July 144 
2013 and January 2016 were prospectively collected. Biopsy was undertaken where 145 
technically feasible and safe. Inflammatory markers, ESR (normal value < 20mm/hr) and CRP 146 
(normal value < 5mg/L), were measured within 1-14 days of the FDG-PET scan.  147 
18F-FDG-PET images were acquired using either a Discovery DST or VCT scanner prior to 148 
October 2014 and one of two GE PET/CT 710 scanners after this date. An injected activity 149 
dose of 350 MBq 18F-FDG was injected intravenously. Images were acquired 90 minutes 150 
after the injection. Image acquisition was performed ode with a field of view covering the 151 
head to mid-thigh using a setting of 4 minutes per bed position with 5-8 bed positions.  152 
Images were reconstructed using the ordered subsets expectation maximization algorithm 153 
with a reconstructed slice thickness of 3.27mm and pixel size 4.7mm.  The CT component of 154 
the scans was acquired at 120 kVp and 65 mAs without administration of oral or intravenous 155 
contrast agent.  156 
Each PET scan was reported in consensus by two PET experts firstly with a qualitative 157 
analysis comparing to blood pool avidity, then quantitative analysis with measurement of 158 
the maximum standard uptake value (SUVmax).  159 
FDG-avidity on PET was categorized as negative, low grade (SUVmax<4), and high grade 160 
(SUVmax≥4). FDG-avidity was used as a proxy for inflammation based on previous human 161 
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and animal studies [13].  162 
Perivascular distribution of RPF was classified as typical. 163 
Data was collected on demographics, clinical presentation, radiological, histopathological 164 
and serological parameters, treatments and treatment responses. A hybrid standard had to 165 
be used with regard to malignancy – if biopsy (open or percutaneous) was not carried out, 166 
follow up was used as confirmation of benign disease. Treatment response was defined as 167 
any shrinkage of mass, reduction in SUVmax on PET, or normalisation of serum inflammatory 168 
markers where no other cause for raised markers was identified. 169 
In previously untreated patients the starting dose of steroids used was 20mg twice daily.  170 
Descriptive statistics were used to summarise the data. Percentages were used for 171 
categorical data. Statistical analysis was with student t test for continuous variables and the 172 















78 patients underwent 101 PET scans. 78/101(77%) of these scans were performed at the 186 
time of first consultation in our RPF service and 23/101 (23%) as part of follow up. Median 187 
follow-up: 16 months (range 6-42 months). Baseline characteristics of the patients are 188 
outlined in table 2. 189 
 190 
Diagnosing malignancy: FDG-PET vs biopsy (table 3) 191 
69/78 (88%) patients had both FDG-PET and a histological diagnosis from image-guided or 192 
surgical biopsy. In 9/78(11%) biopsy was felt to be unsafe or not possible.   193 
Negative PET (image 1a) 24/69 (35%); 0/24 (0%) malignant. NPV 100% (95% CI: 0.95-.097) 194 
Positive PET (image 1b) 45/69 (65%): 195 
Low grade FDG-avidity 26/45 (58%); 0/28 (0%) malignant 196 
High grade FDG-avidity typical distribution (image 1b) 11/45 (24%); 0/11 (0%) 197 
malignant 198 
High grade FDG-avidity atypical distribution (image 1c) 8/45 (18%); 4/8 (50%) 199 
malignant  200 
All 4 malignant cases (2 lymphoma, 1 adrenal cancer, 1 metastatic melanoma) were 201 
highly FDG-avid and the avidity was not peri-vascular. All 4 were reported as ‘highly 202 
suspicious for malignancy’ prior to biopsy giving a sensitivity of 100% for diagnosing 203 
malignancy. 4 patients with high FDG-avidity and atypical distribution had benign histology; 204 
3/4 (75%) IgG4-related RPF. The PPV of an atypical high avidity PET for detecting malignancy 205 
is 50% (95% CI: 0.12-0.43). 206 
 207 
Predicting response to steroids (table 4) 208 
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62/78(79%) patients were prescribed steroids 209 
47/62(76%) patients underwent FDG-PET  210 
14/47(28%) negative (image 1a); 24/47(49%) low-grade FDG-avidity (SUVmax<4; image 1d); 211 
11/47(23%) high-grade FDG-avidity (SUVmax≥4; image 1b)  212 
Response to steroids corresponded to degree of initial FDG uptake on PET (table 3).  213 
Patients with high-grade FDG-avidity on PET (median SUVmax 9.2) were more likely to 214 
respond to steroids than patients with low-grade FDG-avidity (median SUVmax 3.1) or 215 
negative PET  (high grade 9/11 (82%) vs low grade 3/24(12%), p<0.005 value; vs negative 216 
0/14(0%); p<0.005). 217 
 218 
Diagnosing inflammatory activity: FDG-PET vs serum inflammatory markers (table 5) 219 
CRP was recorded at the time of 101/101(100%) PET scans and ESR for 84/101(83%).  220 
Relationship between FDG-PET findings and CRP+/- ESR (if tested) are outlined in table 5. In 221 
29/101 (29%) of scans there was discordance between FDG-PET findings and inflammatory 222 
markers.  223 
Inflammatory markers have a sensitivity of 71% and specificity of 62% for detecting 224 
active/inflammatory RPF if FDG-PET is used as a proxy for inflammatory activity within the 225 
RPF [13].  226 
In 19/38 (50%) scans there was FDG uptake within the RPF despite normal markers. In 17/19 227 
(90%) of these the FDG uptake was low grade (SUVmax<4) and in 2/19 (10%) avidity was 228 
high grade (SUVmax>8) but localized e.g. over a short segment of the iliac artery (image 3). 229 
In these 2 cases patients responded well to steroids with improvement in pain and decrease 230 
in FDG-avidity.  231 




9/101(9%) PET scans showed incidental increase in FDG uptake in other organs; duodenum 234 
(3), stomach (1), colon (2), lung (1), axilla (1) and thyroid (1). All 9 patients were referred for 235 
further evaluation. Two had very significant findings: one patient was diagnosed with 236 
metastatic axillary melanoma (image 4a); and another was diagnosed with Wegner’s 237 
granulomatosis following lung biopsy (image 4b). Four had no pathology on endoscopy and 238 
one was diagnosed with duodenitis. The patient with uptake in the thyroid was diagnosed 239 


















This study suggests 18F-FDG-PET has the potential to improve clinical decision-making in 256 
RPF. It appears to be able to identify patients that are at high risk or low risk of malignancy 257 
pre-biopsy; it may help guide decisions regarding commencement or cessation of steroid 258 
treatment; and it can reveal plaques of inflammatory RPF not detected by serum 259 
inflammatory markers. 260 
 261 
The existing literature on PET in RPF consists mainly of case reports and small heterogenous 262 
retrospective analyses. These are outlined in table 1. They are essentially preliminary studies 263 
that have pointed to a possible role for FDG-PET in RPF but have not been able to fully 264 
explore or define this role. In common with many other rare diseases, specialised clinical 265 
services are lacking making it difficult to study different aspects of the disease in a 266 
systematic manner. Our aim with this study was to evaluate FDG-PET prospectively in a 267 
larger cohort of RPF patients. 268 
 269 
None of the 24 patients with a negative FDG-PET proved to have malignancy on biopsy or 270 
developed malignancy during follow up. This suggests that a biopsy may not be required 271 
when there is no uptake within the RPF mass. It is however known that not all cancers, 272 
particularly if small, generate a positive FDG-PET, but it would seem that cancers of the type 273 
and volume that might mimic RPF are very rarely FDG negative [14,15]. 274 
Malignancy in the retroperitoneum was identified in 4 cases, all of whom had both a highly 275 
avid FDG-PET and non-typical distribution of avidity. Idiopathic RPF tends to have a peri-276 
vascular distribution of avidity whereas the avidity of malignancy is more dispersed (image 277 




Half the patients with high avidity and atypical distribution on FDG-PET proved to have 280 
malignancy. Of the others, 75% had features on biopsy in suggestive of IgG4-related RPF. 281 
IgG4-related RPF is a complex disorder [16] whose clinical significance is debated but it may 282 
represent a more aggressive subtype of RPF [2,17].  283 
 284 
Two further points are worthy of mention about the clinical utility of FDG-PET. Firstly, it may, 285 
on occasion, be more accurate than biopsy for detecting malignancy. In one case (image 2) 286 
two biopsies at the referring hospital had shown fibrosis; PET appearances led to a third 287 
targeted biopsy diagnosing lymphoma. Secondly, PET may reveal clinically significant extra-288 
abdominal disease; high volume axillary melanoma in one patient (image 4a) and Wegener’s 289 
granulomatosis (image 4b) in another. 290 
 291 
To date no cancer has been identified in patients with avid FDG-PET and typical peri-aortic 292 
distribution of avidity suggestive of peri-aortitis. This finding may have clinical value because 293 
biopsy in these situations can be challenging due to the risk of arterial injury. Currently we 294 
would continue to recommend biopsy if technically feasible but it may be in time that biopsy 295 
is not required in these cases. 296 
 297 
The presumed basis of steroid treatment in RPF depends on the suppression of inflammation 298 
[18]. What has not been clear to date is whether steroids have therapeutic benefit in the 299 
absence of inflammation. None of the 14 (0%) patients with negative FDG-PET and only 300 
3/24(12%) with low-grade avidity on FDG-PET (SUVmax<4) had a measurable response to 301 
steroid treatment. By contrast 9/11 (82%) patients with high-grade avidity responded.  302 
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These findings may be of value in decisions regarding initiation or continuation of steroid 303 
therapy. The morbidity of oral steroids is considerable with over 80% complaining of ≥1 side 304 
effect [19] and an individualised approach based on prediction of response is therefore 305 
desirable. Our findings will need validation in larger cohorts, particularly of steroid naïve 306 
patients but our policy is to avoid continuation or commencement of steroids in patients 307 
with a negative FDG-PET.  308 
 309 
A noteworthy observation is that inflammatory activity within RPF plaques may not always 310 
be associated with elevations in serum inflammatory markers. In 29/101 (29%) PET scans 311 
there was discordance between PET findings and serum markers. 19/38(50%) of scans 312 
demonstrated avidity despite normal serum markers. Whilst the majority of avidity in these 313 
cases was low grade, two patients had intense localised avidity.   314 
By contrast, 10/63 (16%) PET scans were negative despite raised serum inflammatory 315 
markers. In these patients, raised markers may be a reflection of systemic autoimmune 316 
diseases, infection or the consequences multiple interventions to manage acute 317 
complications of RPF. The value of FDG-PET when markers are raised may be the knowledge 318 
it provides about the degree of inflammation within the anatomical area of interest. This 319 
could have clinical implications as drug treatment may not be worthwhile in patients who 320 
have a negative FDG-PET despite raised serum inflammatory markers due to other causes.  321 
By extension, serum inflammatory markers alone are probably not sufficient for monitoring 322 
disease activity or evaluating treatment response. 323 
 324 
There are a number of limitations to this study. This study is of only 78 patients. However, a 325 
cohort of 78 patients accrued over 3 years does represent a high volume RPF practice. The 326 
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biggest clinical study of RPF to date accrued 180 patients over 11 years [5]. Clearly though 327 
our findings will need to be validated across wider populations.  328 
Secondly, the majority of patients in this study were tertiary referrals; many had been 329 
heavily pre-investigated and pre-treated and could represent a group with particularly 330 
problematic RPF. Our practice continues to accrue fresh untreated patients in whom our 331 
findings can be tested and validated. 332 
Thirdly, due to the evolution of the study over time and the heterogeneity of the clinical 333 
scenarios it was not possible to investigate or treat all the patients uniformly. Nevertheless, 334 
the patients have been managed by the same multi-disciplinary team in an effort to deliver 335 
as consistent an approach as possible. 336 
 337 
Conclusion 338 
In this study of RPF patients investigated prospectively with 18F-FDG-PET we conclude that:  339 
 Retroperitoneal malignancy mimicking RPF appears to be highly avid on PET and has 340 
an atypical anatomical distribution 341 
 A negative 18F-FDG-PET may be useful in excluding retroperitoneal malignancy – 342 
0/24 patients with negative PET had malignancy on biopsy 343 
 Steroids may not be beneficial if the 18F-FDG-PET is negative – 0/14 patients with a 344 
negative PET had a response 345 
 29% of patients had discordance between serum inflammatory markers and 18F-FDG 346 
–PET findings, raising questions about the validity of surveillance schedules based on 347 
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